CD80 and focal segmental glomerulosclerosis: Studies investigating minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) utilizing multiple antibodies and assays found no significant upregulation of podocyte B7-1 in these conditions, casting doubt on the efficacy of B7-1 inhibitory treatment (195).